Abstract: A method for determining an amount of functional albumin includes providing a test sample containing a defined amount of albumin of unknown binding capacity and a reference sample containing the same defined amount of albumin having a reference binding capacity, incubating the test and reference samples with a defined amount of at least one albumin-binding marker M under conditions that allow formation of complexes of the at least one albumin-binding marker M and albumin (M:A), removing the complexes, detecting a presence or an amount of unbound marker M in the samples after removal of the complex (M:A) through a first and a second test strips that allow for a determination of an amount of unbound marker M, and determining the amount of functional albumin based on the presence or the amount detected of marker M.

Abstract: A method for determining an amount of functional albumin includes providing a test sample containing a defined amount of albumin of unknown binding capacity and a reference sample containing the same defined amount of albumin having a reference binding capacity, incubating the test and reference samples with a defined amount of at least one albumin-binding marker M under conditions that allow formation of complexes of the at least one albumin-binding marker M and albumin (M:A), removing the complexes, detecting a presence or an amount of unbound marker M in the samples after removal of the complex (M:A) through a first and a second test strips that allow for a determination of an amount of unbound marker M, and determining the amount of functional albumin based on the presence or the amount detected of marker M.

Abstract: Determining the relative binding capacity of albumin (A), and amount of functional albumin, involves at least two measurement solutions of a test and reference sample. The measurement solutions contain an albumin-binding marker M. The marker in the measurement solution of the test and reference samples exceeds the presumed available albumin binding capacity. The test sample contains a defined amount of albumin of unknown binding capacity. The reference sample contains the same defined amount of albumin having a reference binding capacity. The measurement solutions are incubated under conditions that allow M:A complexes to form. The M:A complexes are removed. The presence or amount of unbound marker M in the solutions is detected after M:A complex removal by a test strip that allows determination of the unbound marker. The relative binding capacity of albumin in the test sample based on the presence or detected amounts of unbound marker is determined.

Abstract: Determining the relative binding capacity of albumin (A), and amount of functional albumin, involves at least two measurement solutions of a test and reference sample. The measurement solutions contain an albumin-binding marker M. The marker in the measurement solution of the test and reference samples exceeds the presumed available albumin binding capacity. The test sample contains a defined amount of albumin of unknown binding capacity. The reference sample contains the same defined amount of albumin having a reference binding capacity. The measurement solutions are incubated under conditions that allow M:A complexes to form. The M:A complexes are removed. The presence or amount of unbound marker M in the solutions is detected after M:A complex removal by a test strip that allows determination of the unbound marker. The relative binding capacity of albumin in the test sample based on the presence or detected amounts of unbound marker is determined.

Abstract: A method for preparing a leukocyte preparation from a leukocyte fraction and a correspondingly prepared or obtainable leukocyte preparation and its use. The methods include: a) sedimenting the leukocyte fraction removing leukocyte supernatant from the sediment, wherein the leukocyte supernatant is collected or remains in a leukocyte container, b) sedimenting the leukocytes in the leukocyte container, c) washing the sediment in the leukocyte container with a saline solution, and d) resuspending the sediment in the leukocyte container in a storage solution.

Abstract: A method for preparing a leukocyte preparation from a leukocyte fraction and a correspondingly prepared or obtainable leukocyte preparation and its use. The method includes: a) sedimenting the leukocyte fraction removing leukocyte supernatant from the sediment, wherein the leukocyte supernatant is collected or remains in a leukocyte container, b) sedimenting the leukocytes in the leukocyte container, c) washing the sediment in the leukocyte container with a saline solution, and d) resuspending the sediment in the leukocyte container in a storage solution.

Abstract: The invention relates to a clay mineral for use as an agent for reducing the concentration of inorganic phosphate in liquids, in particular in bodily fluids or dialysis liquids, in order to treat hyperphosphatemia, in particular in a renal replacement therapy, wherein before use, the clay mineral is thermally treated at a temperature between 400° C. and 800° C., preferably between 500° C. and 700° C., in particular preferably at 550° C., over a time period of 60 min to 240 min, preferably 90 min to 180 min, in particular preferably 120 min.

Abstract: The present invention relates to a method for treating blood composition disorders and blood function disorders. Said method comprises steps, in which blood or blood plasma of a patient is brought into extracorporeal contact with a second fluid (bioequivalent), wherein said second fluid is blood or modified blood, which comprises at least granulocytes, thrombocytes, and erythrocytes. Furthermore, the invention relates to devices for performing said method and to the use of such a device or blood or modified blood, which comprises granulocytes, thrombocytes, and erythrocytes, for treating blood composition disorders and blood function disorders.

Abstract: The invention relates to a clay mineral for use as an agent for reducing the concentration of inorganic phosphate in liquids, in particular in bodily fluids or dialysis liquids, in order to treat hyperphosphatemia, in particular in a renal replacement therapy, wherein before use, the clay mineral is thermally treated at a temperature between 400° C. and 800° C., preferably between 500° C. and 700° C., in particular preferably at 550° C., over a time period of 60 min to 240 min, preferably 90 min to 180 min, in particular preferably 120 min.

Abstract: A method for preparing a leukocyte preparation from a leukocyte fraction and a correspondingly prepared or obtainable leukocyte preparation and its use. The method includes: a) sedimenting the leukocyte fraction removing leukocyte supernatant from the sediment, wherein the leukocyte supernatant is collected or remains in a leukocyte container, b) sedimenting the leukocytes in the leukocyte container, c) washing the sediment in the leukocyte container with a saline solution, and d) resuspending the sediment in the leukocyte container in a storage solution.

Abstract: The invention relates to a method for the extracorporeal qualitative or semi-quantitative determination of the amount of indicators for the systemic inflammatory response system (SIRS) or sepsis in the blood, blood serum, blood plasma, other body fluids or lavages or their constituents of human or animal subjects. In order to provide a test which is better than that of the prior art, with which the presence and/or the severity of SIRS or sepsis can be rapidly, economically, reliably and reproducibly determined in a sample, such as blood serum of a patient.

Abstract: A device and method for invasive blood pressure measurement in a vascular access under continuous blood flows in a treatment device in extracorporeal detoxification methods is provided. Systemic arterial pressure is directly measured using an existing vascular access for dialysis, or in which the systemic arterial pressure and the temporal progression of such pressure are determined indirectly. A valve-controlled bypass system which goes around a blood pumping unit is provided so that the blood flow in the treatment device is not interrupted, and alarms are suppressed The bypass module is easily connectable to measuring equipment on various treatment units without having to adjust the same.

Abstract: The present invention relates to a method for treating blood composition disorders and blood function disorders. Said method comprises steps, in which blood or blood plasma of a patient is brought into extracorporeal contact with a second fluid (bioequivalent), wherein said second fluid is blood or modified blood, which comprises at least granulocytes, thrombocytes, and erythrocytes. Furthermore, the invention relates to devices for performing said method and to the use of such a device or blood or modified blood, which comprises granulocytes, thrombocytes, and erythrocytes, for treating blood composition disorders and blood function disorders.

Abstract: The invention relates to a method for increasing and/or decreasing the concentration of immunomodulatory-active substances in substance mixtures which contain potentially immunomodulatory-active substances, and corresponding device for carrying out said method

Abstract: A process and set-up of therapeutic immunomodulation is provided for medicine. Many illnesses (i.e. Sepsis) are, among other things, characterized by a disruption of the immune system. In spite of previous therapies using antibiotics, the mortality rate is still very high. The administration of individual cytokins has not yet resulted in any convincing results. The use of cells in an extra-corporal circulation that can adsorb or self-release immunomodulatory effect substances is a completely new type of complex therapeutic approach to such illnesses, which leads to an improvement in the health of the affected patients.

Abstract: The present invention provides a process of separating substances bound to a first protein in a first liquid by means of a membrane separating the first liquid from a second liquid, the process comprising the steps of: a) impregnating the membrane by passing along the membrane a solution comprising a first acceptor protein having an acceptor function for the substances to be separated; b) dialyzing the first liquid against the second liquid, the second liquid comprising a second acceptor protein having an acceptor function for the substances to be separated, wherein the membrane separating the first and second liquids contains tunnel-like structures that permit passage of the substances to be separated to the second liquid but exclude passage of the first protein and the second acceptor protein.